OxyContin maker will stop promoting opioids to doctors

February 10, 2018
OxyContin maker will stop promoting opioids to doctors
This Feb. 19, 2013 file photo shows OxyContin pills arranged for a photo at a pharmacy in Montpelier, Vt. The maker of the powerful painkiller said it will stop marketing opioid drugs to doctors, a surprise reversal after lawsuits blaming the company for helping trigger the current drug abuse epidemic. OxyContin has long been the world's top-selling opioid painkiller and generated billions in sales for privately-held Purdue. (AP Photo/Toby Talbot, File)

The maker of the powerful painkiller OxyContin said it will stop marketing opioid drugs to doctors, a surprise reversal following lawsuits that blamed the company for helping trigger the current drug abuse epidemic.

OxyContin has long been the world's top-selling opioid painkiller. It generated billions in sales for privately-held Purdue.

The pill, a time-release version of oxycodone, was hailed as a breakthrough treatment for when it was approved in late 1995. But some users quickly discovered they could get a heroin-like high by crushing the pills and snorting or injecting the entire dose at once.

Purdue's promotions exaggerated the drug's safety and risks of addiction, leading to and federal investigations. But the drug continued to rack up blockbuster sales.

Explore further: FDA panel: Not enough data to OK "abuse-deterrent" opioid

Related Stories

FDA panel: Not enough data to OK "abuse-deterrent" opioid

July 26, 2017
A panel of Food and Drug Administration advisers voted against approving a new opioid painkiller with a unique feature for deterring abuse: It releases a deep-blue dye if someone tries to get high by crushing, chewing or ...

Alabama files lawsuit against opioid manufacturer

February 6, 2018
Alabama on Tuesday filed a lawsuit against the manufacturer of OxyContin and other opioids, becoming the latest state seeking to hold drug companies accountable for an addiction epidemic.

Fearing abuse, US blocks generic OxyContin (Update)

April 16, 2013
U.S. health regulators will require generic versions of the best-selling painkiller OxyContin to include recent formulation changes designed to make the pill harder to abuse.

US city sues maker of painkiller OxyContin

January 20, 2017
A small US city on Thursday filed a lawsuit against Purdue Pharma, the maker of the pain reliever OxyContin, accusing the company of helping fuel an opioid crisis that has devastated the town.

OxyContin maker bows out of meeting on harder-to-abuse drug

June 30, 2015
The makers of the potent painkiller OxyContin have pulled out of a federal meeting to review the company's harder-to-abuse version of the much-debated drug.

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

gzurbay
not rated yet Feb 10, 2018
Nothing like permitting a company to close the barn door after all the horses are out and the scamming of sales way in excess of the prescription need have flourished and established a presence in the medical system. Why should society not demand criminal punishment for what has been done with total lack of self oversight?? As always white collar crime takes a toll - and is not brought to justice. No wonder it seems the criminal element is in charge of "business".

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.